Webinar: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment (2020)
Course Director: Benjamin R. Lee, MD
Treatment of renal cell carcinoma has changed with expanding indications for Robotic Partial nephrectomy and inclusion of new FDA approved treatments for advanced RCC. This course will focus on didactic case discussions using video tape analysis of surgical treatment, setup and successful completion of Robotic Partial nephrectomy, complication management and how to optimize outcomes. Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors. There will be discussion focus on how to monitor, and algorithms for when to switch treatment.
This educational activity is supported by independent educational grants from:
- Bristol-Myers Squibb
- Pfizer, Inc.
- Sanofi Genzyme
- Advanced Practice Providers (Nurse Practitioners and Physician Assistants)
Upon completion of this activity, participants will be able to:
- State how to manage bleeding complications of robotic partial nephrectomy.
- Describe the algorithm of Immunotherapy treatment of advanced Renal Cell Carcinoma.
- Explain how to minimize positive margin rates of robotic partial nephrectomy.
All times are Eastern
5:00 pm Welcome, Housekeeping Notes, Knowledge Assessment
5:10 pm Faculty Introduction/Learning Objectives
Benjamin R Lee MD, University of Arizona College of Medicine
5:13 pm Advanced RCC management: TKIs, Immunotherapy, checkpoint inhibitors. Which to use & when to switch.
Oliver Sartor MD, Tulane Cancer Center and Tulane Medical School
5:40 pm Complications Panel: Tips & Tricks for getting out of trouble, Video analysis
Benjamin R Lee MD
6:05 pm Case Discussion: Challenging Management dilemmas
Chandru Sundaram MD, University of Indiana
6:30 pm Adjourn and Credit Claim Instructions
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment (2020) will be held virtually on Wednesday, September 2 at 5:00 PM EST.
Click here to join the webinar.
Prior to joining, you will be taken to a GoToWebinar registration page; follow the instructions to be let into the webinar.
Education Council Disclosures
AUA Office of Education Staff has nothing to disclose.
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA Participant Information and Policies
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:
The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
SPECIAL ASSISTANCE/DIETARY NEEDS:
The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation